CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Episodes 181-195 of 739
MET and Other Emerging Targets in Metastatic NSCLC
MinuteCE®MET and Other Emerging Targets in Metastatic NSCLC
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
MinuteCE®Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
MinuteCE®Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
- advertisement
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
MinuteCE®Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
MinuteCE®Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
MinuteCE®Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
MinuteCE®Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
- advertisement
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CEAddressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
CME/CEADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
